Are patients whose study partners are spouses more likely to be eligible for Alzheimer's disease clinical trials?

Dementia and Geriatric Cognitive Disorders

Volumn 33, Issue 5, 2012, Pages 334-340

  Grill, Joshua D ^a   Monsell, Sarah ^b   Karlawish, Jason ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Caregiver; Clinical trials; Dementia; Recruitment; Study partner

Indexed keywords

ADULT CHILD; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; HACHINSKI ISCHEMIA SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NURSING HOME; PRIORITY JOURNAL; RATING SCALE; RESIDENTIAL AREA; SPOUSE; STUDY DESIGN;

ADULT; ADULT CHILDREN; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; CHILD OF IMPAIRED PARENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; SPOUSES;

EID: 84863096887     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000339361     Document Type: Article

References (22)

1. Grill JD, Karlawish J: Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther 2010;2:34
2. Alzheimer's Association: 2008 Alzheimer's disease facts and figures. Alzheimers Dement 2008;4:110-133
3. Alzheimer's Association: Alzheimer's association and national alliance for caregiving. Families care: Alzheimer's disease caregiving in the United States, 2004. www.alz.org 2004
4. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003;289:2819-2826
5. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ: High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA 2008;300: 1774-1783
6. Quinn JF, Raman R, Thomas RG, Yurko- Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS: Docosahexaenoic acid supplementation and ognitive decline in Alzheimer disease: A randomized trial. JAMA 2010;304: 1903-1911
7. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS: A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011;77:556-563
8. Tariot PN, Aisen P, Cummings J, Jakimovich L, Schneider L, Thomas R, Becerra L, Loy R: The ADCS valproate neuroprotection trial: Primary efficacy and safety results. Alzheimer Dement J Alzheimer Assoc 2009;5: P84-P85
9. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS: A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011;76: 1389-1394
10. Folstein MF, Folstein SE, McHugh PR: 'Minimental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
11. Schneider LS, Olin JT, Lyness SA, Chui HC: Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997; 45:923-928
12. Conde-Sala JL, Garre-Olmo J, Turro-Garriga O, Vilalta-Franch J, Lopez-Pousa S: Differential features of burden between spouse and adult-child caregivers of patients with Alzheimer's disease: An exploratory comparative design. Int J Nurs Stud 2010;47: 1262-1273
13. Conde-Sala JL, Garre-Olmo J, Turro-Garriga O, Lopez-Pousa S, Vilalta-Franch J: Factors related to perceived quality of life in patients with Alzheimer's disease: The patient's perception compared with that of caregivers. Int J Geriatr Psychiatry 2009;24:585-594
14. Conde-Sala JL, Garre-Olmo J, Turro-Garriga O, Vilalta-Franch J, Lopez-Pousa S: Quality of life of patients with Alzheimer's disease: Differential perceptions between spouse and adult child caregivers. Dement Geriatr Cogn Disord 2010;29:97-108
15. Norton MC, Piercy KW, Rabins PV, Green RC, Breitner JC, Ostbye T, Corcoran C, Welsh-Bohmer KA, Lyketsos CG, Tschanz JT: Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. J Gerontol B Psychol Sci Soc Sci 2009;64: 560-568
16. Janevic MR, Connell CM: Racial, ethnic, and cultural differences in the dementia caregiving experience: Recent findings. Gerontologist 2001;41:334-347
17. Alzheimer's Association: 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010;6:158-194
18. Mehta KM, Yin M, Resendez C, Yaffe K: Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology 2005;65:159-162
19. Lerner AJ, McClendon MJ, Sami SA, Ogrocki PK, Adams KB, Smyth KA: Factors affecting usage patterns of memantine in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22:137-143
20. Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, Jarvik L, Manly J, McRae T, Murphy GM Jr, Olin JT, Regier D, Sano M, Mintzer JE: Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. Int Psychogeriatr 2007;19:539-558
21. Livney MG, Clark CM, Karlawish JH, Cartmell S, Negron M, Nunez J, Xie SX, Entenza- Cabrera F, Vega IE, Arnold SE: Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center. Am J Geriatr Psychiatry 2011;19:430-439
22. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA: The uniform data set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord 2006;20:210-216